Dr John Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US, and has consulted to the World Health Organization and the World Bank.

After earning his medical degree (MBBS) from the University of Western Australia, Dr Cullity undertook advanced training in haematology-oncology at QEII Medical Centre.

Dr Cullity then moved to the United Kingdom to complete Royal College of Physicians examinations. He also completed a Master of Science at the London School of Economics and an MBA at The Wharton School, University of Pennsylvania.

After a period consulting to World Health Organisation and The World Bank, Dr Cullity worked as Director of Health Economics (Oncology) & Strategic Pricing at Schering-Plough, and then for seven years at Sanofi-Aventis in three roles: Director, Health Economics (Oncology), Senior Director and Head of Strategic Pricing, and Senior Director of Business Development & Licensing (Oncology).

Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm, and established Torreya Insights focusing on transactions advisory. During this time, he managed numerous licensing / M&A transactions and participated in the establishment of several biotech companies.

He remains a director of Theraly Fibrosis Inc (spin-out from Johns Hopkins University), Haemalogix Pty Ltd (Australian immune-oncology company) and Ceramedix Holdings LLC (spin-out from Memorial Sloan Kettering Cancer Center).

To view Dr John Cullity’s LinkedIn profile, please click here.